embody vs altRx vs Medvi: Our Top Three, One Table
Last updated: Sep 1, 2026
Medically reviewed by Francheska Capistrano, RMT, MPH · Medical Content Reviewer
Medically reviewed on Reviewed · Written by Treatments Hub Research Team
We may earn a commission from links on this page - it never affects our rankings (how we stay objective).
Here’s the short version
Thirty dollars separates these three, and none of them asks for a commitment - so this comparison is really about what each adds on top of the same compounded semaglutide. embody keeps it lean: $49 flat at every dose, free 1-2 day shipping, and a full refund if a provider doesn't approve you. altRx charges $89 and is the only one with a brand-name shelf - Ozempic, Zepbound and Wegovy at published cash prices - plus Buy Now, Pay Later. Medvi's $99 promo is all-inclusive with video visits, a free dietician and care coaching.
Compounded GLP-1 from $49/month; not FDA-approved, free expedited delivery
Visit embodyembody vs altRx vs Medvi: side by side
Real published prices and terms - the differences that actually decide this matchup.
| embody | altRx | Medvi | |
|---|---|---|---|
| Semaglutide | $49/mo, flat at every dose | $89/mo (reg. $199), flat at every dose | $99/mo promo (reg. $199), all-inclusive |
| Tirzepatide | $99/mo | $149/mo (reg. $299) | $166/mo promo (reg. $299) |
| Billing & commitment | Monthly - no commitment, cancel anytime | Monthly - pause or cancel anytime; Buy Now, Pay Later | Monthly, all-inclusive - no surprise charges; HSA/FSA approved |
| Shipping | Free 1-2 day, tracked & insured | Free nationwide delivery | Free shipping |
| Support | Licensed doctors, medical director & nursing team | Licensed provider review (physician, PA, or NP) | Video visits + free dietician & care coaching |
| Guarantee / refund | Full refund if you're not approved | - | - |
| Standout | LegitScript-certified; 503A pharmacies | Brand-name shelf: Ozempic $1,149 · Zepbound $1,249 · Wegovy $1,579 | All-inclusive price; HSA/FSA approved |
Our verdict
All three bill monthly with no prepaid term, so the price gap is the honest starting point: $49, $89, $99. Pay the minimum and move fast: embody - cheapest here, quickest shipping, and the refund-if-not-approved policy removes the main risk of trying. Think brand-name Ozempic or Zepbound might be in your future: altRx - it's the only one of the three where that switch happens without changing providers, and BNPL softens the brand prices. Want a person in the loop - video visits, a dietician, someone to call: Medvi. There's no legitimacy gap to worry about: all three run licensed-provider review and dispense through regulated pharmacies.
embody vs altRx vs Medvi: FAQs
Which is cheapest: embody, altRx or Medvi?
For compounded semaglutide: embody at $49/month flat, then altRx at $89/month promotional (regularly $199), then Medvi at $99/month promotional (regularly $199) all-inclusive. For tirzepatide: embody $99, altRx $149 (regularly $299), Medvi $166 promotional (regularly $299). All three bill monthly with no prepaid commitment.
Can I get brand-name Ozempic, Zepbound or Wegovy from any of them?
Only altRx. Alongside its $89/month compounded semaglutide it publishes cash prices for brand-name medication - Ozempic at $1,149, Zepbound at $1,249 and Wegovy at $1,579 per month - with Buy Now, Pay Later available. embody and Medvi focus on compounded GLP-1s.
Do any of these require a long-term commitment?
No - all three bill month to month. embody adds a full refund if a licensed provider doesn't approve you for treatment, altRx lets you pause or cancel anytime, and Medvi's all-inclusive rate is HSA/FSA approved with no surprise charges.
Break it down two at a time
The head-to-head comparisons between these providers.
Medical disclaimer
This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.
Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.
Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.
Sources & medical references
Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.
- 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
- 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
- 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
- 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
- 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
- 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
- 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)

